Cardiovascular outcomes with angiotensin II receptor blockers: Clinical implications of recent trials

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 391-397

  Baumhäkel, Magnus ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Angiotensin receptor blockers; Cardiovascular outcome; Clinical trials

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 83155168745     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S17168     Document Type: Review

References (31)

1. Allender S, Scarborough P, Peto V, et al. European Cardiovascular Disease Statistics. 2008 ed. Available at: http://www.heartstats.org. Accessed June 2, 2010.
2. Werner C, Baumhakel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97:418-431.
3. Bakris G, Böhm M, Dagenais G, et al. Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol. 2008;97:713-725.
4. Friedrich EB, Teo KK, Böhm M. ACE inhibition in secondary prevention: are the results controversial? Clin Res Cardiol. 2006;95: 61-67.
5. Baumhakel M, Böhm M. Telmisartan prevents cardiovascular events in a broad group of at-risk patients. Expert Opin Pharmacother. 2009; 10:3113-3117.
6. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I. Oxidative stress and atherogenesis. Circulation. 2002;105:393-396.
7. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I. Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850-2870.
8. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
9. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
10. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363:2022-2031.
11. Sawada T, Yamada H, Dahlof B, et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO Heart Study. Eur Heart J. 2009;30: 2461-2469.
12. International Diabetes Federation. The Diabetes Atlas. 3rd ed, 2006. Available at: http://www.eatlas.idf.org. Accessed June 2, 2010.
13. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
14. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
15. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.
16. Teo K, Yusuf S, Anderson C, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. (ONTARGET®/ TRANSCEND®) trials. Am Heart J. 2004;148:52-61.
17. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364: 907-917.
18. Food and Drug Administration. FDA drug safety communication: ongoing safety review of Benicar and cardiovascular events. June 11, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/Post marketDrugSafetyInformationforPatientsandProviders/ucm215222. htm. Accessed April 5, 2011.
19. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
20. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
21. Dickstein K, Kjekshus J; OPTIMAAL steering committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360:752-760.
22. Pitt B, Poole-Wilson P, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
23. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840-1848.
24. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.
25. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359:2456-2467.
26. Cice G, Di Benedetto A, D'Isa S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56:1701-1708.
27. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncol. 2010;11:627-636.
28. Julius S, Kjeldsen S, Weber M. Angiotensin-receptor blockade and the risk of cancer. Omission of VALUE trial data invalidates conclusions. Lancet Oncol. 2010;11:820-821.
29. The ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens. 2011;29:623-635.
30. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
31. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.